Medical Research and News

07/13/2022

Suvorexant May Ease Symptoms During Opioid Withdrawal Therapy

Learn more ->

Small pilot study suggests suvorexant may improve sleep, reduce opioid withdrawal and craving during buprenorphine/naloxone taper

06/27/2022

FDA: JUUL E-Cigarette Products Banned in US

Learn more -> https://www.empr.com/home/news/fda-juul-e-cigarette-products-banned-in-us/

06/15/2022

Fezolinetant Cuts Vasomotor Symptoms in Menopause

Learn more -> https://www.empr.com/home/news/fezolinetant-cuts-vasomotor-symptoms-in-menopause/

06/01/2022

Replication-Deficient Jynneos Recommended for Orthopoxvirus

Learn more -> https://www.empr.com/home/news/replication-deficient-jynneos-recommended-for-orthopoxvirus/

05/19/2022

FDA Expands Baby Formula Market to Foreign Suppliers

Learn more -> https://www.empr.com/home/news/fda-expands-baby-formula-market-to-foreign-suppliers/

04/28/2022

Significant Smoking Cessation Observed With Cytisinicline in Phase 3 Trial

Learn more ->

The placebo-controlled ORCA-2 study evaluated the safety and efficacy of cytisinicline as a treatment for smoking cessation in 810 adult smokers.

04/21/2022

Many Medicare Beneficiaries Do Not Fill High-Price Prescriptions

Learn more -> https://www.empr.com/home/news/many-medicare-beneficiaries-do-not-fill-high-price-prescriptions/

04/12/2022

Posttraumatic Epilepsy More Likely to Be Drug Resistant

Learn more -> https://www.empr.com/home/news/posttraumatic-epilepsy-more-likely-to-be-drug-resistant/

03/31/2022

Mini-Slings for Stress Incontinence in Women

In this randomized noninferiority trial comparing two surgical treatments for stress urinary incontinence in women, mini-slings were noninferior to midurethral slings with respect to patient-reported success at 15 months, and the between-group difference remained similar at 3 years. Dyspareunia was more common with mini-slings.

Learn more -> https://www.nejm.org/doi/full/10.1056/NEJMoa2111815?query=featured_home

03/29/2022

Fintepla Approved for Lennox-Gastaut Syndrome

Learn more -> https://www.empr.com/home/news/fintepla-approved-for-lennox-gastaut-syndrome/

03/24/2022

Darolutamide in Metastatic Prostate Cancer

Standard therapy for metastatic, hormone-sensitive prostate cancer is androgen-deprivation therapy, usually with docetaxel. A large, multinational, phase 3 trial assessed the addition of the androgen-receptor blocker darolutamide to standard therapy. At 4 years, survival was higher with darolutamide than with placebo (62.7% vs. 50.4%), with no major differences in the frequency of adverse events.

Learn more -> https://www.nejm.org/doi/full/10.1056/NEJMoa2119115?query=featured_home

03/22/2022

Consequences of the crisis in Ukraine on cancer care

Learn more -> https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00130-9/fulltext